What is Transmedics Group's earnings per share (EPS)?

Transmedics Group (TMDX) reported diluted earnings per share of $4.87 for fiscal year 2025. This represents a 382.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Transmedics Group Financials

TMDX

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Transmedics Group (TMDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 86/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Transmedics Group has an operating margin of 17.9%, meaning the company retains $18 of operating profit per $100 of revenue. This results in a moderate score of 62/100, indicating healthy but not exceptional operating efficiency. This is up from 8.5% the prior year.

Growth

Transmedics Group's revenue surged 37.1% year-over-year to $605.5M, reflecting rapid business expansion. This strong growth earns a score of 95/100.

Leverage

Transmedics Group carries a low D/E ratio of 1.26, meaning only $1.26 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 76/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 7.14, Transmedics Group holds $7.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Transmedics Group converts 22.1% of revenue into free cash flow ($133.6M). This strong cash generation earns a score of 80/100.

Returns

100

Transmedics Group earns a strong 40.2% return on equity (ROE), meaning it generates $40 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 15.5% the prior year.

Altman Z-Score Safe

4.64

Transmedics Group scores 4.64, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.5B) relative to total liabilities ($595.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

6/9

Transmedics Group passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.01x

For every $1 of reported earnings, Transmedics Group generates $1.01 in operating cash flow ($192.8M OCF vs $190.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

7.9x

Transmedics Group earns $7.9 in operating income for every $1 of interest expense ($108.6M vs $13.8M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$605.5M

YoY+37.1%

5Y CAGR+88.2%

Transmedics Group generated $605.5M in revenue in fiscal year 2025. This represents an increase of 37.1% from the prior year.

EBITDA

$135.8M

YoY+137.1%

Transmedics Group's EBITDA was $135.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 137.1% from the prior year.

Net Income

$190.3M

YoY+436.6%

Transmedics Group reported $190.3M in net income in fiscal year 2025. This represents an increase of 436.6% from the prior year.

EPS (Diluted)

$4.87

YoY+382.2%

Transmedics Group earned $4.87 per diluted share (EPS) in fiscal year 2025. This represents an increase of 382.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$133.6M

YoY+265.0%

Transmedics Group generated $133.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 265.0% from the prior year.

Cash & Debt

$488.9M

YoY+45.0%

5Y CAGR+81.9%

Transmedics Group held $488.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.00

Transmedics Group paid $0.00 per share in dividends in fiscal year 2025.

Shares Outstanding

34M

YoY+1.9%

5Y CAGR+4.8%

Transmedics Group had 34M shares outstanding in fiscal year 2025. This represents an increase of 1.9% from the prior year.

Margins & Returns

Gross Margin

59.9%

YoY+0.6pp

5Y CAGR-5.0pp

Transmedics Group's gross margin was 59.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

17.9%

YoY+9.4pp

5Y CAGR+120.8pp

Transmedics Group's operating margin was 17.9% in fiscal year 2025, reflecting core business profitability. This is up 9.4 percentage points from the prior year.

Net Margin

31.4%

YoY+23.4pp

5Y CAGR+143.6pp

Transmedics Group's net profit margin was 31.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 23.4 percentage points from the prior year.

Return on Equity

40.2%

YoY+24.7pp

5Y CAGR+67.9pp

Transmedics Group's ROE was 40.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 24.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$69.1M

YoY+23.4%

5Y CAGR+29.7%

Transmedics Group invested $69.1M in research and development in fiscal year 2025. This represents an increase of 23.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$59.3M

YoY-54.3%

5Y CAGR+164.8%

Transmedics Group invested $59.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 54.3% from the prior year.

TMDX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$605.5M+37.1%	$441.5M+82.7%	$241.6M+158.5%	$93.5M+208.8%	$30.3M+18.0%	$25.6M
Cost of Revenue	$242.7M+35.2%	$179.5M+105.0%	$87.5M+210.5%	$28.2M+209.6%	$9.1M+1.1%	$9.0M
Gross Profit	$362.8M+38.4%	$262.1M+70.1%	$154.1M+136.1%	$65.3M+208.5%	$21.2M+27.2%	$16.6M
R&D Expenses	$69.1M+23.4%	$56.0M+55.2%	$36.1M+34.5%	$26.8M+20.2%	$22.3M+18.4%	$18.8M
SG&A Expenses	$185.2M+9.8%	$168.6M+41.0%	$119.6M+71.0%	$69.9M+82.6%	$38.3M+58.3%	$24.2M
Operating Income	$108.6M+189.6%	$37.5M+230.5%	-$28.7M+8.6%	-$31.4M+20.3%	-$39.4M-49.4%	-$26.4M
Interest Expense	$13.8M-4.4%	$14.4M+33.5%	$10.8M+189.6%	$3.7M-3.8%	$3.9M-2.8%	$4.0M
Income Tax	-$82.8M-26292.7%	$316K+119.2%	-$1.6M-2589.4%	$66K	N/A	$0
Net Income	$190.3M+436.6%	$35.5M+241.7%	-$25.0M+30.9%	-$36.2M+18.1%	-$44.2M-53.8%	-$28.7M
EPS (Diluted)	$4.87+382.2%	$1.01+231.2%	$-0.77+37.4%	$-1.23+23.1%	$-1.60-37.9%	$-1.16

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$160.8M+11.8%	$143.8M-8.6%	$157.4M+9.6%	$143.5M+18.0%	$121.6M+11.8%	$108.8M-4.9%	$114.3M+18.0%	$96.8M
Cost of Revenue	$67.3M+13.7%	$59.2M-2.5%	$60.8M+9.9%	$55.3M+11.5%	$49.6M+3.5%	$47.9M+6.4%	$45.0M+22.1%	$36.9M
Gross Profit	$93.4M+10.5%	$84.6M-12.4%	$96.6M+9.5%	$88.2M+22.5%	$72.0M+18.4%	$60.8M-12.2%	$69.3M+15.5%	$60.0M
R&D Expenses	$20.7M+35.7%	$15.3M-4.2%	$15.9M-7.1%	$17.2M+4.2%	$16.5M+15.4%	$14.3M+2.9%	$13.9M+21.8%	$11.4M
SG&A Expenses	$51.4M+11.8%	$46.0M+4.4%	$44.1M+1.1%	$43.6M-7.0%	$46.9M+10.0%	$42.7M-0.6%	$42.9M+18.6%	$36.2M
Operating Income	$21.3M-8.7%	$23.3M-36.3%	$36.6M+33.2%	$27.4M+217.5%	$8.6M+120.3%	$3.9M-68.6%	$12.5M+0.7%	$12.4M
Interest Expense	$3.4M-3.9%	$3.5M+0.4%	$3.5M+0.4%	$3.5M-3.1%	$3.6M-1.3%	$3.6M-0.2%	$3.6M+0.7%	$3.6M
Income Tax	-$83.8M-6402.3%	-$1.3M-201.0%	$1.3M+28.3%	$994K+653.0%	$132K+355.2%	$29K+170.7%	-$41K-120.9%	$196K
Net Income	$105.4M+333.3%	$24.3M-30.3%	$34.9M+35.9%	$25.7M+274.5%	$6.9M+62.6%	$4.2M-65.4%	$12.2M0.0%	$12.2M
EPS (Diluted)	N/A	$0.66-28.3%	$0.92+31.4%	$0.70	N/A	$0.12-65.7%	$0.350.0%	$0.35

TMDX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.1B+32.9%	$804.1M+13.9%	$706.0M+154.8%	$277.1M+105.5%	$134.9M-11.3%	$152.0M
Current Assets	$637.8M+28.3%	$497.2M-2.6%	$510.7M+102.4%	$252.3M+112.5%	$118.7M-19.1%	$146.8M
Cash & Equivalents	$488.9M+45.0%	$337.1M-14.6%	$394.8M+96.2%	$201.2M+686.5%	$25.6M+4.1%	$24.6M
Inventory	$48.9M+5.0%	$46.6M+5.2%	$44.2M+114.7%	$20.6M+38.7%	$14.9M+24.5%	$11.9M
Accounts Receivable	$84.3M-13.8%	$97.7M+53.7%	$63.6M+130.3%	$27.6M+365.3%	$5.9M-13.5%	$6.9M
Goodwill	$11.5M0.0%	$11.5M-3.7%	$12.0M	N/A	N/A	N/A
Total Liabilities	$595.3M+3.4%	$575.5M+1.2%	$568.8M+533.7%	$89.8M+33.9%	$67.0M+39.3%	$48.1M
Current Liabilities	$89.3M+49.1%	$59.9M+9.1%	$54.9M+132.2%	$23.7M+1.8%	$23.2M+95.6%	$11.9M
Long-Term Debt	N/A	N/A	N/A	$58.7M+66.8%	$35.2M+1.6%	$34.7M
Total Equity	$473.1M+107.0%	$228.6M+66.6%	$137.2M-26.8%	$187.4M+176.1%	$67.9M-34.7%	$103.9M
Retained Earnings	-$277.9M+40.6%	-$468.2M+7.0%	-$503.7M-5.2%	-$478.7M-8.2%	-$442.4M-11.1%	-$398.2M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.1B+12.9%	$946.0M+6.2%	$890.5M+6.3%	$837.5M+4.2%	$804.1M+2.4%	$785.6M+3.6%	$758.6M+4.8%	$723.8M
Current Assets	$637.8M+4.0%	$613.0M+9.8%	$558.1M+10.3%	$505.9M+1.8%	$497.2M+1.0%	$492.5M-3.3%	$509.3M+4.3%	$488.3M
Cash & Equivalents	$488.9M+4.8%	$466.7M+16.4%	$401.1M+29.1%	$310.6M-7.9%	$337.1M+2.1%	$330.1M-9.0%	$362.8M+3.6%	$350.2M
Inventory	$48.9M+9.8%	$44.5M+14.5%	$38.9M-10.4%	$43.4M-6.8%	$46.6M-10.7%	$52.2M+7.2%	$48.7M+0.3%	$48.5M
Accounts Receivable	$84.3M+4.4%	$80.7M-23.0%	$104.9M-26.2%	$142.0M+45.3%	$97.7M+8.4%	$90.1M+11.1%	$81.2M-1.0%	$81.9M
Goodwill	$11.5M0.0%	$11.5M0.0%	$11.5M0.0%	$11.5M0.0%	$11.5M0.0%	$11.5M0.0%	$11.5M-3.7%	$12.0M
Total Liabilities	$595.3M+0.8%	$590.8M+3.2%	$572.4M+0.2%	$571.2M-0.7%	$575.5M0.0%	$575.7M+1.2%	$568.7M+0.8%	$564.4M
Current Liabilities	$89.3M+12.0%	$79.7M+40.8%	$56.6M+1.8%	$55.6M-7.2%	$59.9M-0.2%	$60.0M+10.5%	$54.3M+8.2%	$50.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$473.1M+33.2%	$355.2M+11.7%	$318.1M+19.4%	$266.3M+16.5%	$228.6M+8.9%	$209.9M+10.5%	$189.9M+19.1%	$159.5M
Retained Earnings	-$277.9M+27.5%	-$383.3M+6.0%	-$407.7M+7.9%	-$442.6M+5.5%	-$468.2M+1.4%	-$475.1M+0.9%	-$479.3M+2.5%	-$491.5M

TMDX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$192.8M+295.1%	$48.8M+474.6%	-$13.0M+71.6%	-$45.8M-58.7%	-$28.9M+4.6%	-$30.3M
Capital Expenditures	$59.3M-54.3%	$129.7M-14.6%	$151.8M+1175.3%	$11.9M+238.4%	$3.5M+673.4%	$455K
Free Cash Flow	$133.6M+265.0%	-$80.9M+50.9%	-$164.9M-185.6%	-$57.7M-78.3%	-$32.4M-5.4%	-$30.7M
Investing Cash Flow	-$59.3M+54.2%	-$129.3M+33.3%	-$194.0M-455.8%	$54.5M+86.3%	$29.3M+170.4%	-$41.6M
Financing Cash Flow	$16.9M-26.3%	$22.9M-94.3%	$400.4M+138.4%	$167.9M+11955.1%	$1.4M-98.2%	$75.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$34.5M-50.4%	$69.6M-24.1%	$91.6M+3308.7%	-$2.9M-114.5%	$19.7M+186.8%	$6.9M-73.3%	$25.7M+848.7%	-$3.4M
Capital Expenditures	$15.5M+103.5%	$7.6M-16.0%	$9.1M-66.4%	$27.0M+98.7%	$13.6M-71.8%	$48.2M+102.8%	$23.8M-46.2%	$44.2M
Free Cash Flow	$19.0M-69.3%	$61.9M-24.9%	$82.5M+376.1%	-$29.9M-593.5%	$6.1M+114.6%	-$41.3M-2214.9%	$2.0M+104.1%	-$47.6M
Investing Cash Flow	-$15.5M-103.5%	-$7.6M+16.0%	-$9.1M+66.4%	-$27.0M-98.7%	-$13.6M+71.5%	-$47.8M-101.0%	-$23.8M+46.2%	-$44.2M
Financing Cash Flow	$3.1M-14.9%	$3.6M-48.6%	$7.1M+134.1%	$3.0M+155.3%	$1.2M-84.9%	$7.9M-26.1%	$10.6M+234.1%	$3.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TMDX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	59.9%+0.6pp	59.4%-4.4pp	63.8%-6.1pp	69.8%-0.1pp	69.9%+5.0pp	64.9%
Operating Margin	17.9%+9.4pp	8.5%+20.4pp	-11.9%+21.7pp	-33.6%+96.6pp	-130.3%-27.4pp	-102.9%
Net Margin	31.4%+23.4pp	8.0%+18.4pp	-10.4%+28.4pp	-38.8%+107.3pp	-146.1%-34.0pp	-112.1%
Return on Equity	40.2%+24.7pp	15.5%+33.8pp	-18.2%+1.1pp	-19.3%+45.8pp	-65.2%-37.5pp	-27.7%
Return on Assets	17.8%+13.4pp	4.4%+8.0pp	-3.5%+9.5pp	-13.1%+19.7pp	-32.8%-13.9pp	-18.9%
Current Ratio	7.14-1.2	8.30-1.0	9.30-1.4	10.66+5.6	5.11-7.2	12.36
Debt-to-Equity	1.26-1.3	2.52-1.6	4.15+3.8	0.31-0.2	0.52+0.2	0.33
FCF Margin	22.1%+40.4pp	-18.3%+49.9pp	-68.2%-6.5pp	-61.8%+45.3pp	-107.0%+12.8pp	-119.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	58.1%-0.7pp	58.8%-2.6pp	61.4%-0.1pp	61.5%+2.3pp	59.2%+3.3pp	55.9%-4.6pp	60.6%-1.3pp	61.9%
Operating Margin	13.2%-3.0pp	16.2%-7.0pp	23.2%+4.1pp	19.1%+12.0pp	7.1%+3.5pp	3.6%-7.3pp	10.9%-1.9pp	12.8%
Net Margin	65.5%+48.6pp	16.9%-5.3pp	22.2%+4.3pp	17.9%+12.3pp	5.6%+1.8pp	3.9%-6.8pp	10.7%-1.9pp	12.6%
Return on Equity	22.3%+15.4pp	6.9%-4.1pp	11.0%+1.3pp	9.6%+6.6pp	3.0%+1.0pp	2.0%-4.4pp	6.4%-1.2pp	7.6%
Return on Assets	9.9%+7.3pp	2.6%-1.3pp	3.9%+0.8pp	3.1%+2.2pp	0.9%+0.3pp	0.5%-1.1pp	1.6%-0.1pp	1.7%
Current Ratio	7.14-0.5	7.69-2.2	9.86+0.8	9.10+0.8	8.30+0.1	8.20-1.2	9.37-0.3	9.72
Debt-to-Equity	1.26-0.4	1.66-0.1	1.80-0.3	2.15-0.4	2.52-0.2	2.74-0.3	2.99-0.5	3.54
FCF Margin	11.8%-31.3pp	43.1%-9.4pp	52.4%+73.3pp	-20.8%-25.8pp	5.0%+43.0pp	-38.0%-39.7pp	1.7%+50.9pp	-49.2%

Similar Companies

Integer Hldgs Corp ITGR

$3.0B

$6.5B

$5.6B

$3.5B

$1.6B

Frequently Asked Questions

What is Transmedics Group's annual revenue?

Transmedics Group (TMDX) reported $605.5M in total revenue for fiscal year 2025. This represents a 37.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Transmedics Group's revenue growing?

Transmedics Group (TMDX) revenue grew by 37.1% year-over-year, from $441.5M to $605.5M in fiscal year 2025.

Is Transmedics Group profitable?

Yes, Transmedics Group (TMDX) reported a net income of $190.3M in fiscal year 2025, with a net profit margin of 31.4%.

What is Transmedics Group's EBITDA?

Transmedics Group (TMDX) had EBITDA of $135.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Transmedics Group's gross margin?

Transmedics Group (TMDX) had a gross margin of 59.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Transmedics Group's operating margin?

Transmedics Group (TMDX) had an operating margin of 17.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Transmedics Group's net profit margin?

Transmedics Group (TMDX) had a net profit margin of 31.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Transmedics Group's return on equity (ROE)?

Transmedics Group (TMDX) has a return on equity of 40.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Transmedics Group's free cash flow?

Transmedics Group (TMDX) generated $133.6M in free cash flow during fiscal year 2025. This represents a 265.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Transmedics Group's operating cash flow?

Transmedics Group (TMDX) generated $192.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Transmedics Group's total assets?

Transmedics Group (TMDX) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Transmedics Group's capital expenditures?

Transmedics Group (TMDX) invested $59.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Transmedics Group spend on research and development?

Transmedics Group (TMDX) invested $69.1M in research and development during fiscal year 2025.

How many shares does Transmedics Group have outstanding?

Transmedics Group (TMDX) had 34M shares outstanding as of fiscal year 2025.

What is Transmedics Group's current ratio?

Transmedics Group (TMDX) had a current ratio of 7.14 as of fiscal year 2025, which is generally considered healthy.

What is Transmedics Group's debt-to-equity ratio?

Transmedics Group (TMDX) had a debt-to-equity ratio of 1.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Transmedics Group's return on assets (ROA)?

Transmedics Group (TMDX) had a return on assets of 17.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Transmedics Group's Altman Z-Score?

Transmedics Group (TMDX) has an Altman Z-Score of 4.64, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Transmedics Group's Piotroski F-Score?

Transmedics Group (TMDX) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Transmedics Group's earnings high quality?

Transmedics Group (TMDX) has an earnings quality ratio of 1.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Transmedics Group cover its interest payments?

Transmedics Group (TMDX) has an interest coverage ratio of 7.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Transmedics Group?

Transmedics Group (TMDX) scores 86 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.